Drug Profile

Research programme: astatine conjugate therapeutics - ARRONAX/INSERM/Telix

Latest Information Update: 28 May 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ARRONAX; Institut national de la sante et de la recherche medicale; Telix Pharmaceuticals
Class Antineoplastics; Radiopharmaceuticals
Mechanism of Action Ionising radiation emitters

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 May 2022 No recent reports of development identified for research development in Cancer in Australia
30 May 2018 Telix Pharmaceuticals and Osaka University enter into a research collaboration for Alpha nuclide research
16 Apr 2018 Telix Pharmaceuticals establishes collaboration with ARRONAX and INSERM for the development of astatine conjugate therapeutics in Cancer

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com